← All trials
NCT03313596
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2013
- Primary completion
- Dec 31, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Capital Medical UniversityCollaborator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.